Long-Term Results Show Promise for MCO-010 in Retinitis Pigmentosa

At the 2025 annual meeting of the American Society of Retina Specialists (ASRS), new data brought encouraging news for families affected by retinitis pigmentosa (RP). Dr. David Liao, MD, PhD, presented 126-week (over 2 years) follow-up results from the RESTORE (REMAIN) study of MCO-010 , an innovative optogenetic therapy for advanced RP. What the Study Found Patients with advanced RP, including those with very limited vision (20/1600 or worse), received a one-time injection of MCO-010. After more than two years of follow-up, many patients showed meaningful and lasting improvements in vision . On average, patients gained the equivalent of 3 lines on a standard eye chart (Snellen). The therapy continued to show a favorable safety profile , with no major adverse effects reported. How MCO-010 Works Unlike traditional gene therapies that target specific genetic mutations, MCO-010 is gene-agnostic — meaning it can potentially help patients regardless of their exact RP mutation. Here’s what makes it unique: Uses optogenetics to make non-photoreceptor retinal cells sensitive to light. Specif